{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,18]],"date-time":"2026-06-18T11:54:29Z","timestamp":1781783669678,"version":"3.54.5"},"reference-count":28,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,10,17]],"date-time":"2025-10-17T00:00:00Z","timestamp":1760659200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100000272","name":"National Institute for Health and Care Research","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000272","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100013342","name":"NIHR Imperial Biomedical Research Centre","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100013342","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","cysticfibrosisjournal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Cystic Fibrosis"],"published-print":{"date-parts":[[2026,3]]},"DOI":"10.1016\/j.jcf.2025.10.008","type":"journal-article","created":{"date-parts":[[2025,10,25]],"date-time":"2025-10-25T01:46:13Z","timestamp":1761356773000},"page":"290-295","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Research and development spending versus revenues after approval for CFTR modulators"],"prefix":"10.1016","volume":"25","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8007-1076","authenticated-orcid":false,"given":"Jonathan","family":"Guo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-0973-3194","authenticated-orcid":false,"given":"Grace","family":"Hennessy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benedict","family":"Young","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew","family":"Hill","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jcf.2025.10.008_bib0001","doi-asserted-by":"crossref","first-page":"1343","DOI":"10.1001\/jama.2013.278129","article-title":"Pricing for orphan drugs: will the market bear what society cannot?","volume":"310","author":"O\u2019Sullivan","year":"2013","journal-title":"JAMA"},{"key":"10.1016\/j.jcf.2025.10.008_bib0002","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2021.746710","article-title":"A comparative analysis of pricing and reimbursement of cystic Fibrosis transmembrane conductance regulator modulators in Europe","volume":"12","author":"Abdallah","year":"2021","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.jcf.2025.10.008_bib0003","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1016\/j.jcf.2020.07.017","article-title":"Projecting the impact of delayed access to elexacaftor\/tezacaftor\/ivacaftor for people with Cystic Fibrosis","volume":"20","author":"Stanojevic","year":"2021","journal-title":"J Cystic Fibr"},{"key":"10.1016\/j.jcf.2025.10.008_bib0004","doi-asserted-by":"crossref","DOI":"10.1016\/j.jcf.2022.04.007","article-title":"Current prices versus minimum costs of production for CFTR modulators","volume":"21","author":"Guo","year":"2022","journal-title":"J Cyst Fibros"},{"key":"10.1016\/j.jcf.2025.10.008_bib0006","doi-asserted-by":"crossref","DOI":"10.1002\/ppul.26954","article-title":"International disparities in diagnosis and treatment access for cystic fibrosis","author":"Guo","year":"2024","journal-title":"Pediatr Pulmonol"},{"key":"10.1016\/j.jcf.2025.10.008_bib0009","doi-asserted-by":"crossref","first-page":"1569","DOI":"10.1001\/jamainternmed.2017.3601","article-title":"Research and development spending to bring a single cancer drug to market and revenues after approval","volume":"177","author":"Prasad","year":"2017","journal-title":"JAMA Intern Med"},{"key":"10.1016\/j.jcf.2025.10.008_bib0010","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/j.jhealeco.2016.01.012","article-title":"Innovation in the pharmaceutical industry: new estimates of R&D costs","volume":"47","author":"DiMasi","year":"2016","journal-title":"J Health Econ"},{"key":"10.1016\/j.jcf.2025.10.008_bib0011","series-title":"The antidote: inside the world of new pharma","author":"Werth","year":"2014"},{"key":"10.1016\/j.jcf.2025.10.008_bib0013","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1186\/s13023-018-0990-4","article-title":"Estimating the clinical cost of drug development for orphan versus non-orphan drugs","volume":"14","author":"Jayasundara","year":"2019","journal-title":"Orphanet J Rare Dis"},{"key":"10.1016\/j.jcf.2025.10.008_bib0014","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1016\/j.drudis.2012.02.005","article-title":"Orphan drug development: an economically viable strategy for biopharma R&D","volume":"17","author":"Meekings","year":"2012","journal-title":"Drug Discov Today"},{"key":"10.1016\/j.jcf.2025.10.008_bib0015","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1038\/d41573-021-00190-9","article-title":"Clinical development times for innovative drugs","volume":"21","author":"Brown","year":"2022","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.jcf.2025.10.008_bib0016","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1038\/d41573-024-00131-2","article-title":"Comprehensive measurement of biopharmaceutical R&D investment","volume":"23","author":"Chandra","year":"2024","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.jcf.2025.10.008_bib0017","article-title":"Elexacaftor 100 mg \/tezacaftor 50 mg \/ ivacaftor 75 mg film-coated tablets co-packaged with ivacaftor 150 mg film-coated tablets","year":"2021","journal-title":"Vertex Pharmaceuticals"},{"key":"10.1016\/j.jcf.2025.10.008_bib0018","article-title":"From blockbuster to \u201cnichebuster\u201d: how a flawed legislation helped create a new profit model for the drug industry","volume":"370","author":"Marselis","year":"2020","journal-title":"BMJ"},{"key":"10.1016\/j.jcf.2025.10.008_bib0019","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1038\/d41573-025-00049-3","article-title":"Top companies and drugs by sales in 2024","volume":"24","author":"Verdin","year":"2025","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.jcf.2025.10.008_bib0020","first-page":"599","article-title":"Real-world outcomes and direct care cost before and after elexacaftor\/tezacaftor\/ivacaftor initiation in commercially insured members with cystic fibrosis","volume":"29","author":"Marshall","year":"2023","journal-title":"J Manag Care Spec Pharm"},{"key":"10.1016\/j.jcf.2025.10.008_bib0021","doi-asserted-by":"crossref","first-page":"1611","DOI":"10.1002\/ppul.24178","article-title":"Healthcare expenditures for privately insured US patients with cystic fibrosis, 2010\u20132016","volume":"53","author":"Grosse","year":"2018","journal-title":"Pediatr Pulmonol"},{"key":"10.1016\/j.jcf.2025.10.008_bib0022","author":"Angelis","year":"2023","journal-title":"Promoting population health through pharmaceutical policy"},{"key":"10.1016\/j.jcf.2025.10.008_bib0023","doi-asserted-by":"crossref","DOI":"10.1016\/j.jcf.2025.02.010","article-title":"Strategies used to access CFTR modulators in countries without reimbursement agreements","author":"Guo","year":"2025","journal-title":"J Cystic Fibr"},{"key":"10.1016\/j.jcf.2025.10.008_bib0024","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/S0140-6736(24)02352-3","article-title":"Population-health impact of new drugs recommended by the National Institute for Health and Care Excellence in England during 2000\u201320: a retrospective analysis","volume":"405","author":"Naci","year":"2024","journal-title":"The Lancet"},{"key":"10.1016\/j.jcf.2025.10.008_bib0025","doi-asserted-by":"crossref","first-page":"2145","DOI":"10.1001\/jama.2022.5542","article-title":"Trends in prescription drug launch prices","volume":"327","author":"Rome","year":"2022","journal-title":"JAMA"},{"key":"10.1016\/j.jcf.2025.10.008_bib0026","doi-asserted-by":"crossref","first-page":"999","DOI":"10.2217\/cer-2022-0120","article-title":"The next generation of rare disease drug policy: ensuring both innovation and affordability","volume":"11","author":"Pearson","year":"2022","journal-title":"J Comp Eff Res"},{"key":"10.1016\/j.jcf.2025.10.008_bib0027","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1038\/d41587-023-00016-6","article-title":"The world\u2019s first CRISPR therapy is approved: who will receive it?","volume":"42","author":"Sheridan","year":"2024","journal-title":"Nat Biotechnol"},{"key":"10.1016\/j.jcf.2025.10.008_bib0028","doi-asserted-by":"crossref","first-page":"932","DOI":"10.1016\/S2213-2600(23)00297-7","article-title":"Advancing the pipeline of cystic fibrosis clinical trials: a new roadmap with a global trial network perspective","volume":"11","author":"Mayer-Hamblett","year":"2023","journal-title":"Lancet Respir Med"},{"key":"10.1016\/j.jcf.2025.10.008_bib0030","article-title":"Vertex cancels plans for CF triple combo testing in France, citing failed Orkambi negotiations | Fierce Pharma","author":"Sagonowsky","year":"2018","journal-title":"FiercePharma"},{"key":"10.1016\/j.jcf.2025.10.008_bib0031","series-title":"Guidelines for medicine donations, revised","year":"2010"},{"key":"10.1016\/j.jcf.2025.10.008_bib0032","year":"2024","journal-title":"Global Health & Revenue Growth | Voluntary Licensing Report."},{"key":"10.1016\/j.jcf.2025.10.008_bib0033","series-title":"Vertex\u2019s international sales slide with ip \u201cviolation\u201d","author":"Becker","year":"2025"}],"container-title":["Journal of Cystic Fibrosis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1569199325024920?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1569199325024920?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,6,18]],"date-time":"2026-06-18T11:37:17Z","timestamp":1781782637000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1569199325024920"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3]]},"references-count":28,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,3]]}},"alternative-id":["S1569199325024920"],"URL":"https:\/\/doi.org\/10.1016\/j.jcf.2025.10.008","relation":{},"ISSN":["1569-1993"],"issn-type":[{"value":"1569-1993","type":"print"}],"subject":[],"published":{"date-parts":[[2026,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Research and development spending versus revenues after approval for CFTR modulators","name":"articletitle","label":"Article Title"},{"value":"Journal of Cystic Fibrosis","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jcf.2025.10.008","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Author(s). Published by Elsevier B.V. on behalf of European Cystic Fibrosis Society.","name":"copyright","label":"Copyright"}]}}